The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

AngioDynamics (ANGO) Beats Q3 Estimates Amid Strong Med Tech Demand

Key Facts

1AngioDynamics (ANGO) exceeded analyst estimates in its fiscal third-quarter results.

2Revenue rose and losses narrowed, driven by strong demand in the Med Tech sector.

3Gross margin experienced a decline despite the beat on revenue and earnings.

AngioDynamics (ANGO) reported fiscal third-quarter results that surpassed analyst expectations for both revenue and earnings. The company's performance was bolstered by robust demand within its Med Tech division, leading to a notable increase in overall revenue. Consequently, AngioDynamics saw its net losses narrow during the period, reflecting improved operational efficiency in key segments. Despite the top and bottom-line beats, the company reported a decline in gross margins, which may weigh on long-term profitability outlooks. Investors reacted positively to the news, driving the stock price higher in pre-market trading sessions. These results underscore the resilience of the medical technology sector and the company's ability to leverage innovation.

Create Free Account